What we do is we work with partners, which include drug companies, and also includes academic partners and others, to co-develop the drugs. What we're doing is we provide funding, but we also provide guidance, expertise, oversight, and an outlook for the public interest. About half of our staff are research scientists.
On June 4th, 2015. See this statement in context.